OPKO Health (NASDAQ:OPK) Given Outperform Rating at Barrington Research

OPKO Health (NASDAQ:OPK - Get Free Report)'s stock had its "outperform" rating reaffirmed by Barrington Research in a research note issued on Wednesday,Benzinga reports. They presently have a $2.25 target price on the biotechnology company's stock. Barrington Research's target price indicates a potential upside of 30.81% from the company's previous close.

A number of other analysts have also issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday, March 3rd. StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd.

OPKO Health Stock Down 3.4 %

Shares of OPKO Health stock traded down $0.06 on Wednesday, reaching $1.72. The company's stock had a trading volume of 2,554,660 shares, compared to its average volume of 4,640,999. The firm's fifty day simple moving average is $1.61 and its two-hundred day simple moving average is $1.57. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -9.05 and a beta of 1.70. OPKO Health has a 52 week low of $0.86 and a 52 week high of $2.04.

Remove Ads

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. Equities analysts anticipate that OPKO Health will post -0.25 earnings per share for the current year.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average cost of $1.48 per share, with a total value of $740,000.00. Following the purchase, the chief executive officer now directly owns 213,036,477 shares in the company, valued at $315,293,985.96. This represents a 0.24 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have acquired 889,971 shares of company stock worth $1,344,442 over the last 90 days. 47.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its position in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new position in shares of OPKO Health in the third quarter valued at approximately $45,000. Cibc World Markets Corp purchased a new position in OPKO Health during the fourth quarter worth approximately $45,000. Zacks Investment Management acquired a new stake in shares of OPKO Health in the fourth quarter worth $49,000. Finally, Ieq Capital LLC acquired a new stake in OPKO Health during the 4th quarter valued at $52,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.